HC Wainwright Has Negative Forecast for SMMT FY2025 Earnings

Summit Therapeutics PLC (NASDAQ:SMMT) – Analysts at HC Wainwright dropped their FY2025 EPS estimates for shares of Summit Therapeutics in a report issued on Tuesday, October 21st. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($1.47) per share for the year, down from their previous estimate of ($1.03). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Summit Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Summit Therapeutics’ Q4 2025 earnings at ($0.31) EPS, Q1 2026 earnings at ($0.31) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.34) EPS and FY2026 earnings at ($1.28) EPS.

A number of other research analysts also recently commented on SMMT. Wall Street Zen downgraded shares of Summit Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 16th. Piper Sandler initiated coverage on shares of Summit Therapeutics in a research report on Monday, August 18th. They issued a “neutral” rating and a $21.00 price objective for the company. Zacks Research raised shares of Summit Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Summit Therapeutics in a research report on Wednesday, October 8th. Finally, Barclays lifted their price objective on shares of Summit Therapeutics from $13.00 to $16.00 and gave the company an “underweight” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.14.

Summit Therapeutics Price Performance

Shares of SMMT opened at $19.16 on Thursday. The firm has a 50-day moving average of $22.02 and a 200-day moving average of $23.36. Summit Therapeutics has a one year low of $15.55 and a one year high of $36.91. The company has a market cap of $14.26 billion, a PE ratio of -15.45 and a beta of -1.13.

Summit Therapeutics (NASDAQ:SMMT) last issued its quarterly earnings results on Monday, October 20th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.17).

Insider Activity

In other Summit Therapeutics news, CEO Mahkam Zanganeh acquired 5,000 shares of the business’s stock in a transaction on Thursday, September 11th. The stock was purchased at an average price of $18.07 per share, with a total value of $90,350.00. Following the acquisition, the chief executive officer directly owned 556,093,090 shares of the company’s stock, valued at approximately $10,048,602,136.30. This trade represents a 0.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert W. Duggan acquired 5,000 shares of the business’s stock in a transaction on Thursday, September 11th. The stock was acquired at an average cost of $18.07 per share, with a total value of $90,350.00. Following the acquisition, the chief executive officer directly owned 556,093,090 shares in the company, valued at approximately $10,048,602,136.30. This trade represents a 0.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 676,788 shares of company stock valued at $11,969,512 in the last ninety days. 84.90% of the stock is currently owned by insiders.

Institutional Trading of Summit Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SMMT. Janney Montgomery Scott LLC lifted its holdings in shares of Summit Therapeutics by 12.1% during the 1st quarter. Janney Montgomery Scott LLC now owns 17,610 shares of the company’s stock worth $340,000 after acquiring an additional 1,894 shares during the period. Golden State Wealth Management LLC lifted its holdings in shares of Summit Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 1,502 shares of the company’s stock worth $29,000 after acquiring an additional 751 shares during the period. Lisanti Capital Growth LLC bought a new stake in shares of Summit Therapeutics during the 1st quarter worth approximately $1,039,000. Sovran Advisors LLC lifted its holdings in shares of Summit Therapeutics by 25.1% during the 1st quarter. Sovran Advisors LLC now owns 146,528 shares of the company’s stock worth $2,827,000 after acquiring an additional 29,354 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in shares of Summit Therapeutics by 20.1% during the 1st quarter. Principal Financial Group Inc. now owns 246,429 shares of the company’s stock worth $4,754,000 after acquiring an additional 41,279 shares during the period. Institutional investors own 4.61% of the company’s stock.

About Summit Therapeutics

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.